Skip to main content
. Author manuscript; available in PMC: 2020 Mar 6.
Published in final edited form as: ACS Appl Mater Interfaces. 2019 May 10;11(20):18213–18223. doi: 10.1021/acsami.9b03956

Figure 6.

Figure 6.

(A) In vivo T1-map of subcutaneous PC-3 (α2β1 overexpression) prostate tumors in athymic nude mice (n = 6) obtained before and 6–240 h after the intravenous injection of Gd-Cy5.5-PhMV-DGEA (targeted group) or Gd-Cy5.5-PhMV-mPEG (control group). (B) Quantitative analysis of T1 reduction in tumors. (C) Biodistribution of Gd3+ in the main organs of mice after bimodal scanning (240 h postinjection). Noninjected mice were used as the blank control group.